Editorials in 2013

Filter By:

Article Type
Year

  • Moves to give biosimilars nonproprietary names different from brand products are more than a wrangle about words—they could mean biosimilars arrive stillborn to the market.

    Editorial

  • Improving the integration of computational analysis into biology will require better documentation, validation and accessibility of software associated with papers.

    Editorial

  • Three decades after transgenes were first introduced into plants, why do so many consumers remain so negative about genetically modified (GM) food?

    Editorial

  • An international alliance to enable secure sharing of human genomic and clinical data merits both broad support and financial backing from the global research and clinical communities.

    Editorial

  • The Myriad decision to overturn human gene patents is the least of concerns for a diagnostic sector struggling to attract investment.

    Editorial

  • To prevent a popular backlash against the spiraling prices of US prescription medicines, industry needs to do more to address out-of-pocket expenses for patients.

    Editorial

  • Judicious choice of a target tumor antigen for adoptive T-cell therapy remains crucial not only for efficacy but also for avoiding serious toxicities.

    Editorial

  • Nature Biotechnology and other Nature journals are updating editorial policies with the aim of improving transparency and reproducibility.

    Editorial

  • The brand biotech industry is erecting barriers to biosimilars that will slow market entry and torpedo price competition.

    Editorial

  • Genetically defined germ-free animal models colonized with defined microbiota are crucial for progress in microbiome research.

    Editorial

  • Increasing public and private sector cooperation to support long-term, longitudinal population studies is critical to advance translational research on complex diseases.

    Editorial

  • Despite their limitations, in vitro assays are a simple means for assessing the drug sensitivity of a patient's cancer. After consulting experts in the community, we think such assays deserve a second look.

    Editorial

  • A slew of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly parsimonious reimbursement environment.

    Editorial